14 results about "Pharmaceutic industry" patented technology

This utility model relates to a cleanroom air conditioning and dust removal system, belonging to the field of cleanroom technology in the pharmaceutical industry. The system includes a combined cleanroom air conditioning unit, a bag filter, an air supply duct network, a high-efficiency filter air outlet, a return air duct network, a dust removal exhaust hood, a dust removal static pressure box, a dust concentration sensor, and a controller. The bag filter is rigidly connected to the air conditioning unit side-by-side and fixed to the floor of the equipment room, eliminating interference from the equipment to the cleanroom. The outlet of the bag filter is directly connected to the mixing section of the air conditioning unit through the return air duct network, forcibly reusing the dust-removed air as return air. The dust concentration sensor is embedded in the inner wall of the dust removal static pressure box, directly exposed to the dust-laden airflow channel. This application significantly reduces the air conditioning cooling and heating load by physically reducing the demand for fresh air; the centralized layout of the equipment room frees up space in the cleanroom, improving the convenience of operation and maintenance; and the closed-loop dust collection and multi-stage filtration ensure the stability of cleanliness levels D and above.

The invention belongs to the technical field of crystal form drug molecules, and particularly relates to a preparation method and application of a baricitinib and glutaric acid eutectic acetonitrile solvate. The eutectic compound disclosed by the invention is good in solubility, and the bioavailability of the baricitinib is remarkably improved. The preparation process is simple. Good medical industrial application prospects are realized.

The invention belongs to the technical field of crystal form medicine molecules, and particularly relates to a preparation method and application of a baricitinib-saccharin eutectic crystal. Compared with eutectic crystals disclosed in the prior art, the baricitinib-saccharin eutectic crystal disclosed by the invention is high in stability, good in solubility and simple in preparation process. The bioavailability of the baricitinib can be obviously improved, and the baricitinib has a relatively good medical industrial application prospect.

The invention belongs to the technical field of crystal form drug molecules, and particularly relates to baricitinib-maleic acid-gallate. After the three components form the salt, the solubility of baricitinib can be remarkably enhanced, the oral bioavailability is improved, and the salt has a very high patent medicine value and a relatively good application prospect in the medical industry.

This invention relates to the field of medicinal chemistry, specifically disclosing a triazole-fused piperidinone derivative, its preparation method, and its application. The triazole-fused piperidinone derivative has the structure shown in Formula I; wherein, R... 1 Selected from alkyl, phenyl, substituted phenyl, naphthyl ring, furan ring, thiophene ring, or pyridine ring; R 2 Selected from alkyl, allyl, or benzyl; R 3 The derivatives are selected from alkyl, phenyl, substituted phenyl, acyl, or sulfonyl groups. Studies have shown that the triazole-fused piperidinone derivatives described herein possess certain antiviral activity. Furthermore, the preparation method described in this invention can be carried out under mild conditions, is simple to operate, involves few steps, has good functional group compatibility, and yields high results. Therefore, this method has promising application prospects in pharmaceutical industrial production.

The present invention relates to a fibrillar hydrogel comprising an aqueous solution and substantially aligned fibrils composed of collagen and at least one proteoglycan, having viscoelastic characteristics enabling its use in a wide range of industries, including but not limited to the food industry, biomaterial industry, pharmaceutic industry, and cosmetics, as well as for research purposes.

This invention belongs to the field of pharmaceutical technology, specifically relating to the crystal form of 3-(3,5-dichloro-4-hydroxybenzoyl)-1,1-dioxo-2,3-dihydro-1,3-benzothiazole (compound of formula I) and its preparation method. The X-ray powder diffraction pattern of crystal form F of compound I shows diffraction peaks at 2θ values ​​of 12.0°, 14.0°, 16.5°, 20.3°, 21.7°, 23.9°, 24.5°, 28.0°, 28.8°, and 30.1°, with an error range of ±0.2° for the 2θ values. Compared with existing type II and type I crystals and hydrates of compound I, crystal form F of compound I exhibits lower hygroscopicity, higher solubility, and better flowability, thus possessing value for pharmaceutical industrial applications.

The invention belongs to the technical field of crystal form drug molecules, and particularly relates to a new salt crystal form of baricitinib glycolic acid. The obtained baricitinib glycolate crystal form is good in stability and high in solubility. The bioavailability of the baricitinib is remarkably improved, and the baricitinib has a relatively good medical industrial application prospect.

The invention relates to a method for detecting enantiomers and diastereoisomers of lumepirone tosylate, which is used for detecting enantiomers and diastereoisomers of lumepirone tosylate by adopting a high performance liquid chromatography. In the high performance liquid chromatography detection process, a filling agent of a chromatographic column is amylose-tri (4-chloro-3-methyl phenyl carbamate), and a mobile phase comprises alkane, alcohol and amine. The detection method has the advantages of good separation degree, high sensitivity and simple method, and is suitable for inspection and quality control of the lumepirone tosylate isomer in the medical industry, so that the safety of clinical medication is improved.

The invention belongs to the technical field of crystal form drug molecules, and particularly relates to a preparation method and application of a baricitinib and isophthalic acid eutectic dichloromethane solvate. The eutectic compound is high in stability, good in solubility and simple in preparation process. And the bioavailability of the baricitinib is obviously improved. Good medical industrial application prospects are realized.

The application discloses a synthesis process of high-purity sulfonamide chlorodiazine sodium, and belongs to the technical field of medicine industry synthesis, which comprises the following steps: synthesizing a condensate, synthesizing sulfonamide chlorodiazine, and synthesizing sulfonamide chlorodiazine sodium finished product; the condensate is synthesized by mixing an aromatic hydrocarbon solvent, 3,6-dichloropyridazine, p-acetamidobenzenesulfonamide, an acid-binding agent and a catalyst at 20-30 DEG C, and then performing a reflux water separation reaction at 100-120 DEG C; after 6-10 hours of reaction, the temperature is lowered to obtain a condensate liquid; and the catalyst is one of cuprous bromide, cuprous iodide and cuprous chloride. The synthesis process has the advantages of safety and environmental protection, cheap and easily available raw materials, simple process and low production cost, and the prepared sulfonamide chlorodiazine sodium has high yield and high purity.

This invention belongs to the field of pharmaceutical technology, specifically relating to the crystal forms of omaglineline and their preparation methods. This invention provides crystal forms A and C of the hemicalcium hydrate of omaglineline (compound of formula I), and crystal form A of the anhydrous omaglineline (compound of formula II). Compared with the amorphous form, the omaglineline crystal forms of this invention possess superior stability, solubility, hygroscopicity, powder properties, and mechanical properties, and have potential value for industrial pharmaceutical applications. Furthermore, the purification steps in the crystal form preparation method of this invention are simple, adaptable to commercial production routes, and practical.

The application provides a non-classical C-glycoside and a stereospecific synthesis method and application thereof, and the synthesis method comprises the following steps: taking a non-classical sugar-based stannane as a nucleophilic reagent, taking a halogenated hydrocarbon as an electrophilic reagent, and performing a Stille cross-coupling reaction to obtain the non-classical C-glycoside. The non-classical C-glycoside and the stereospecific synthesis method and application thereof provided by the application have the advantages that the synthesis method is simple in process, convenient in operation, high in yield, good in functional group tolerance, strong in stereospecificity, wide in sugar substrate range, and compatible with unprotected sugar and an aqueous phase system; furthermore, the obtained non-classical C-glycoside not only has better antibacterial activity, but also can be used as an active pharmaceutical material, and promotes the technological progress of the pharmaceutical synthesis industry and the pharmaceutical industry.

This invention discloses a refining method for natural eucalyptus oil and its application, relating to the field of plant essential oil refining technology; specifically including the following steps: S1: Add natural eucalyptus oil and zeolite to a distillation kettle, and perform total reflux sequentially under vacuum conditions; adjust the reflux ratio, perform one reflux, collect the distillate as the head fraction; adjust the reflux ratio, perform a second reflux, collect the distillate, and obtain refined eucalyptus oil A; S2: Pack the packing material into a chromatography purification column; load the refined eucalyptus oil A into the chromatography purification column for circulating chromatography, obtain the eluent, and remove the ethanol by vacuum distillation to obtain refined eucalyptus oil; dispense and package to obtain the product; this product can be applied in the pharmaceutical industry and fragrance industry.